Annual report pursuant to Section 13 and 15(d)

13. SEGMENTS (Details)

v3.20.1
13. SEGMENTS (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Revenues $ 29,349,083 $ 16,985,290
Cost of product revenue 39,504,238 42,194,635
Loss from operations (41,424,327) (60,288,944)
Interest and other expense, net (8,419,916) (5,454,501)
Gain on transfer of plasma center asset 11,527,421 0
Loss on extingishment of debt (9,962,495) 0
Net loss (48,279,317) (65,743,445)
Capital expenditures 3,811,838 2,095,600
Depreciation and amortization expense 3,258,148 3,446,398
Total assets 127,090,725 88,876,521
ADMA BioManufacturing    
Revenues 22,176,699 6,797,548
Cost of product revenue 33,306,858 35,485,273
Loss from operations (29,360,522) (45,633,715)
Interest and other expense, net (1,091,993) (1,077,624)
Gain on transfer of plasma center asset 0  
Loss on extingishment of debt 0  
Net loss (30,452,515) (46,711,339)
Capital expenditures 3,772,742 1,580,684
Depreciation and amortization expense 2,789,498 2,608,776
Total assets 100,461,050 57,818,051
Plasma Collection Centers    
Revenues 7,029,550 10,044,908
Cost of product revenue 6,197,380 6,709,362
Loss from operations (1,337,459) (4,470,073)
Interest and other expense, net 13,521 (967)
Gain on transfer of plasma center asset 11,527,421  
Loss on extingishment of debt 0  
Net loss 10,203,483 (4,471,040)
Capital expenditures 39,096 514,916
Depreciation and amortization expense 455,412 814,768
Total assets 3,967,860 5,443,032
Corporate    
Revenues 142,834 142,834
Cost of product revenue 0 0
Loss from operations (10,726,346) (10,185,156)
Interest and other expense, net (7,341,444) (4,375,910)
Gain on transfer of plasma center asset 0  
Loss on extingishment of debt (9,962,495)  
Net loss (28,030,285) (14,561,066)
Capital expenditures 0 0
Depreciation and amortization expense 13,238 22,854
Total assets $ 22,661,815 $ 25,615,438